Show simple item record

dc.contributor.authorNasution, S
dc.contributor.authorRey, Imelda
dc.contributor.authorR Effendi-YS
dc.date.accessioned2019-02-28T02:51:07Z
dc.date.available2019-02-28T02:51:07Z
dc.date.issued2018
dc.identifier.urihttp://repository.usu.ac.id/handle/123456789/70054
dc.descriptionImelda Reyid
dc.description.abstractHypertension is the most common risk factor for cardiovascular disease, stroke, renal failure, and death. Recent drug monitoring studies found non-adherence to BP lowering therapy in 25% to 65% of patients with apparent treatment-resistant hypertension (TRH). This review focuses on the latest development of antihypertensive medication, such as vasopeptidase inhibitors, aldosterone synthase inhibitors, Soluble Epoxide Hydrolase Inhibitors, agonists of natriuretic peptide receptor, Vasoactive Intestinal Peptide Receptor Agonist, a novel mineralocorticoid receptor antagonist, inhibitors of aminopeptidase A, dopamine β-hydroxylase inhibitor, intestinal Na+/H+ exchanger 3 inhibitor and other agents.id
dc.language.isoenid
dc.subjectHypertensionid
dc.subjectAntihypertensiveid
dc.titleThe Latest Development of Antihypertensive Medicationid
dc.typeLecture Papersid


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record